Tirzepatide — Weight & Blood Sugar Management
| Size | 10MG, 20MG, 30MG, 60MG |
|---|
Tirzepatide is the active ingredient in prescription medicines used for specific weight-management or type 2 diabetes indications. This unverified listing is not identified as an FDA-approved finished medicine.
Price range: $75.00 through $185.00
Certificates of Analysis
- Download Tirzepatide 10 mg COA (JPG)
- Download Tirzepatide 20 mg COA (JPG)
- Download Tirzepatide 30 mg COA (JPG)
- Download Tirzepatide 60 mg COA (JPG)
Tirzepatide — Weight & Blood Sugar Management
Tirzepatide acts at GIP and GLP-1 receptors. Approved finished medicines containing tirzepatide have specific indications, eligibility criteria, and prescribing information. Their clinical evidence and approval status cannot automatically be assigned to a bulk ingredient, research vial, or compounded preparation.
At a glance
- Clinical context: weight management or type 2 diabetes care with the appropriate approved medicine.
- Mechanism: dual GIP and GLP-1 receptor activity.
- Selection depends on the exact product, indication, and a licensed clinician’s assessment.
Evidence and intended use
Do not assume this item is Mounjaro or Zepbound. Compounded products are not FDA-approved. Prescription medicines require the appropriate prescribing and dispensing pathway; this CSV does not implement one.
Common question
Is every tirzepatide product FDA-approved?
No. Approval applies to specific finished medicines, not every product using the ingredient name. Confirm the actual manufacturer, formulation, and dispensing source.
Product details
Confirm the exact formulation, strength, package size, and intended use against the supplier label. Refer to the manufacturer documentation for storage and handling information.
| Compound class | Dual GIP and GLP-1 receptor agonist peptide |
|---|---|
| Primary focus | Weight and blood sugar management in approved medicines |
| Size | 10MG, 20MG, 30MG, 60MG |